BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and respiratory disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company's biotherapeutic platforms in clinical development. The Company's products include the Helix Biotherapeutic Delivery System and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix system and clinical support for their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia, and acute myocardial infarction.

Company profile
Ticker
BCDA, BCDAW
Exchange
Website
CEO
Peter Altman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne ...
Former names
Cardo Medical, Inc., CLICKNSETTLE COM INC, NAM CORP, Tiger X Medical, Inc.
SEC CIK
Corporate docs
Subsidiaries
BioCardia Lifesciences, Inc. ...
IRS number
232753988
BCDA stock data
News

Recap: BioCardia Q2 Earnings
10 Aug 22
BioCardia Q2 EPS $(0.14) Beats $(0.25) Estimate, Sales $974.00K Up From $69.00K YoY
10 Aug 22
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
10 Aug 22
Earnings Scheduled For August 10, 2022
10 Aug 22
BioCardia Earnings Preview
9 Aug 22
Press releases
BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call on August 10, 2022
4 Aug 22
BioCardia to Participate in Upcoming Heart and Pulmonary Therapy Development Symposia
12 Jul 22
Thinking about buying stock in BioCardia, Boxed, Zomedica, New Oriental Education, or Garrett Motion?
15 Jun 22
Investment data
Securities sold
Number of investors
Calendar
10 Aug 22
16 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 8.61M | 8.61M | 8.61M | 8.61M | 8.61M | 8.61M |
Cash burn (monthly) | 438.67K | 827.42K | 832K | 999.33K | 881.67K | 931.33K |
Cash used (since last report) | 688.52K | 1.3M | 1.31M | 1.57M | 1.38M | 1.46M |
Cash remaining | 7.93M | 7.32M | 7.31M | 7.05M | 7.23M | 7.15M |
Runway (months of cash) | 18.1 | 8.8 | 8.8 | 7.1 | 8.2 | 7.7 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Jun 22 | Altman Peter | Common Stock | Buy | Acquire P | No | No | 1.46 | 4,500 | 6.57K | 321,197 |
13 May 22 | Altman Peter | Common Stock | Buy | Acquire P | No | No | 1.38 | 2,698 | 3.72K | 348,143 |
12 May 22 | Altman Peter | Common Stock | Payment of exercise | Dispose F | No | No | 1.32 | 31,446 | 41.51K | 316,697 |
12 May 22 | Edward M Gillis | Common Stock | Payment of exercise | Dispose F | No | No | 1.32 | 12,358 | 16.31K | 23,879 |
12 May 22 | McClung David | Common Stock | Payment of exercise | Dispose F | No | No | 1.32 | 20,632 | 27.23K | 76,518 |
12 May 22 | Altman Peter | Common Stock | Buy | Acquire P | No | No | 1.2 | 11,302 | 13.56K | 345,445 |
11 May 22 | Altman Peter | Common Stock | Buy | Acquire P | No | No | 1.3 | 1,000 | 1.3K | 334,143 |
Institutional ownership, Q1 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0 |
Total shares | 0 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Financial report summary
?Competition
Abbott Laboratories • Caladrius Biosciences • Gene Biotherapeutics • ThermoGenesis • Vericel • Plus Therapeutics • Capricor Therapeutics • Mesoblast • Athersys • VistaGen TherapeuticsContent analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
Ambulatory, awaiting, CCS, certified, cleanroom, echocardiography, Exemption, fluoroscopy, formal, fulfilled, fulfilment, futility, Institute, ISO, Japan, July, mononuclear, Ottawa, passage, payment, Pharmaceutical, PMDA, recovery, rehospitalization, relapse, respirator, retroactive, scheduled, survival, sustained, transthoracic, ultrasound, York
Removed:
coupled
Financial reports
Current reports
8-K
Biocardia Reports Second Quarter 2022 Business Highlights and Financial Results
10 Aug 22
8-K
BioCardia Announces First Canadian Clinical Site for CardiAMP Cell Therapy Heart Failure Trial
1 Aug 22
8-K
BioCardia Announces US Patent on Imaging System for Targeting Cardiac Therapies
15 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
10 Jun 22
8-K
Biocardia Reports First Quarter 2022 Business Highlights and Financial Results
11 May 22
8-K
Other Events
12 Apr 22
8-K
Phase I/II Trial Initiation Expected in 3Q 2022
12 Apr 22
8-K
Biocardia Reports 2021 Financial Results and Recent Business Highlights
29 Mar 22
8-K
BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure
22 Mar 22
8-K
BioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Failure Trial into Canada
1 Mar 22
Registration and prospectus
424B5
Prospectus supplement for primary offering
12 Apr 22
S-8
Registration of securities for employees
30 Mar 22
S-8
Registration of securities for employees
30 Mar 21
424B5
Prospectus supplement for primary offering
29 Mar 21
424B5
Prospectus supplement for primary offering
16 Dec 20
424B5
Prospectus supplement for primary offering
15 Dec 20
S-3
Shelf registration
9 Oct 20
424B4
Prospectus supplement with pricing info
18 Jun 20
S-1/A
IPO registration (amended)
15 Jun 20
FWP
Free writing prospectus
8 Jun 20
Other
EFFECT
Notice of effectiveness
21 Oct 20
CORRESP
Correspondence with SEC
18 Oct 20
UPLOAD
Letter from SEC
14 Oct 20
EFFECT
Notice of effectiveness
17 Jun 20
CORRESP
Correspondence with SEC
14 Jun 20
CORRESP
Correspondence with SEC
14 Jun 20
EFFECT
Notice of effectiveness
22 Apr 20
UPLOAD
Letter from SEC
19 Feb 20
UPLOAD
Letter from SEC
16 Dec 19
CORRESP
Correspondence with SEC
4 Dec 19
Ownership
4
BioCardia / Peter Altman ownership change
13 Jun 22
4
BioCardia / Peter Altman ownership change
18 May 22
4
BioCardia / EDWARD M GILLIS ownership change
18 May 22
4
BioCardia / David McClung ownership change
18 May 22
4
BioCardia / Peter Altman ownership change
13 May 22
4
BioCardia / Peter Altman ownership change
2 May 22
4
BioCardia / Peter Altman ownership change
18 Apr 22
4
BioCardia / David McClung ownership change
18 Apr 22
4
BioCardia / EDWARD M GILLIS ownership change
18 Apr 22
SC 13G/A
BioCardia / Francis Capital Management ownership change
14 Feb 22
Patents
Utility
Target site selection, entry and update with automatic remote image annotation
14 Jun 22
Fluoroscopic imaging of a patient's heart is performed by positioning a patient in a sterile field and imaging the heart using a x-ray fluoroscopy system within the sterile to produce a two-dimensional image.
Utility
Multi-Directional Steerable Catheter
2 Jun 22
A bi-directional steerable catheter adapted for delivery into a patient's vasculature.
Utility
Target Site Selection, Entry and Update with Automatic Remote Image Annotation
14 Oct 21
Fluoroscopic imaging of a patient's heart is performed by positioning a patient in a sterile field and imaging the heart using a x-ray fluoroscopy system within the sterile to produce a two-dimensional image.
Utility
Multi-directional steerable catheter
12 Oct 21
A bi-directional steerable catheter adapted for delivery into a patient's vasculature.
Utility
Methods of Measuring Potential for Therapeutic Potency and Defining Dosages for Autologous Cell Therapies
3 Jun 21
Autologous bone marrow cells (BMC) are transplanted to a heterologous site in a patient after a sample of the patient's BMC has been tested and found to have a phenotypic profile which meets minimum criteria for transplantation.
Reddit threads
Daily Discussion Thread - August 10th, 2022
10 Aug 22
Daily Discussion Thread - August 9th, 2022
9 Aug 22
💰💰💰Good morning! #premarket #watchlist 06/15 $ASTL -strong earnings, $BCDA -US Patent on Imaging System for Targeting Cardiac Therapies, $BOXD -June 15, 2022: Oppenheimer 22nd Annual Consumer Growth and E-Commerce Virtual Conference, $CSCW -potential stock offering, $REV -no recent news
15 Jun 22
💰💰💰Good morning! #premarket #watchlist 06/15 $ASTL -strong earnings, $BCDA -US Patent on Imaging System for Targeting Cardiac Therapies, $BOXD -June 15, 2022: Oppenheimer 22nd Annual Consumer Growth and E-Commerce Virtual Conference, $CSCW -potential stock offering, $REV -no recent news
15 Jun 22
💰💰💰Good morning! #premarket #watchlist 06/15 $ASTL -strong earnings, $BCDA -US Patent on Imaging System for Targeting Cardiac Therapies, $BOXD -June 15, 2022: Oppenheimer 22nd Annual Consumer Growth and E-Commerce Virtual Conference, $CSCW -potential stock offering, $REV -no recent news
15 Jun 22
💰💰💰Good morning! #premarket #watchlist 06/15 $ASTL -strong earnings, $BCDA -US Patent on Imaging System for Targeting Cardiac Therapies, $BOXD -June 15, 2022: Oppenheimer 22nd Annual Consumer Growth and E-Commerce Virtual Conference, $CSCW -potential stock offering, $REV -no recent news
15 Jun 22
💰💰💰Good morning! #premarket #watchlist 06/15 $ASTL -strong earnings, $BCDA -US Patent on Imaging System for Targeting Cardiac Therapies, $BOXD -June 15, 2022: Oppenheimer 22nd Annual Consumer Growth and E-Commerce Virtual Conference, $CSCW -potential stock offering, $REV -no recent news
15 Jun 22
Daily Discussion Thread - May 11th, 2022
11 May 22
Daily Discussion Thread - May 10th, 2022
10 May 22
Daily Discussion Thread - May 9th, 2022
9 May 22